The Full List of FDA-Approved Peptides (And What’s Coming Next)

The conversation around peptides right now is noisy, and the noise is coming from both directions. One side dismisses them as fringe and experimental. The other promotes them without context or nuance. Neither is accurate, and both miss the most important point.

Peptides are signalling molecules. They tell your body to do something it already knows how to do: produce more growth hormone, regulate appetite, repair tissue, modulate the immune system. They do not override your body's systems or replace hormones. That mechanism is fundamentally different from the category of drugs most people picture when they hear the word peptide.

And the idea that peptides are some new untested category? That is directly contradicted by the FDA approval list. Here is the full picture.

Why FDA approval is not the only lens that matters

Before getting into the list, one point needs to be made clearly.

People use "not FDA approved" as a reason to dismiss peptides entirely. That concern is understandable up to a point, because FDA approval is a meaningful signal of safety and efficacy for a specific use case. But it is not the whole picture.

Supplements are not FDA approved. Vitamins, fish oil, protein powder, magnesium. None of those go through the FDA approval process, and no one is particularly alarmed by that. The FDA approval framework applies to drugs seeking approval for specific medical indications. It does not cover everything that is safe and evidence-backed.

There are over 7,000 known peptides. Some have been studied rigorously and approved for specific conditions. Some are currently in that process. Others have not been studied at all. The goal here is to help you understand which category each one falls into, so you can make informed decisions rather than reacting to headlines in either direction.

Insulin: over 100 years of peptide therapy

The first FDA approved peptide on this list has been in clinical use since 1922.

Insulin is a peptide hormone, and it received approval over a century ago. Billions of doses, millions of lives saved, and more than 100 years of safety data. It is one of the greatest medicines in human history.

This matters because when people talk about peptides as though they are an entirely new and untested category, insulin is the most immediate rebuttal. Peptide therapy is not new. The framework has been established for a very long time. What is new is the range of applications now being explored.

Semaglutide and tirzepatide: the GLP-1s most people already know

These are the peptides most people are thinking of when GLP-1s come up in conversation, and both are fully FDA approved.

Semaglutide, sold as Ozempic for type 2 diabetes and Wegovy for weight loss, received FDA approval in 2017. It is one of the most studied and prescribed drugs of the last decade, with tens of millions of prescriptions and extensive real-world safety data on top of the clinical trial base.

Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, is a dual agonist targeting both GLP-1 and GIP receptors. It is FDA approved and showing superior weight loss outcomes to semaglutide in head-to-head trials.

Both are widely available through prescription and have robust clinical data behind them. This is the established end of the peptide spectrum.

Tesamorelin: the metabolic health peptide worth knowing about

Tesamorelin received FDA approval in 2010 for the reduction of excess abdominal fat in HIV patients, where treatment side effects caused abnormal fat distribution.

It works by stimulating your body to produce more of its own growth hormone in a natural pattern, rather than injecting growth hormone directly. Clinical data shows significant reductions in visceral fat, which matters because visceral fat is highly inflammatory, drives insulin resistance, and is one of the harder fat depots to shift through diet and exercise alone.

With 15 years of clinical use and a mechanism that works with your body's own systems rather than bypassing them, tesamorelin is one of the most relevant peptides on this list for the metabolic health conversation. I covered it in a full dedicated video, linked above.

Melanotan 1: and why it is not the same as melanotan 2

Melanotan 1 received FDA approval in 2019 for a rare light sensitivity disorder called erythropoietic protoporphyria. It works by stimulating melanin production to protect the skin from light-induced pain.

One important distinction: melanotan 1 is not the same as melanotan 2. Melanotan 2 is a related compound that has circulated widely on the grey market, primarily for aesthetic tanning purposes. It has not received FDA approval for human use. These are different compounds and conflating them is a common source of confusion in this space.

Linaclotide: the gut health peptide

Linaclotide received FDA approval in 2012 for irritable bowel syndrome with constipation and chronic idiopathic constipation.

It works by activating receptors in the gut lining, increasing fluid secretion and decreasing pain signalling. Multiple large phase 3 trials support its approval. This one is less central to the metabolic health conversation but worth including for two reasons: gut health and insulin resistance are directly connected, and it is another clear example of an approved peptide that most people do not realise is a peptide.

Growth hormone: and why tesamorelin has a better long-term profile

Growth hormone has been used clinically since 1985 for growth hormone deficiency and holds FDA approval for multiple indications.

It is worth including here specifically because of its relationship to tesamorelin. Injecting growth hormone directly bypasses your body's own regulatory systems and suppresses natural production over time. Tesamorelin, by contrast, stimulates your own growth hormone production rather than replacing it. That distinction is part of why tesamorelin has a more favourable long-term profile for people considering this pathway.

PT-141: relevant to women specifically

PT-141 received FDA approval in 2019 for hypoactive sexual desire disorder.

This one is particularly relevant to women. Low libido is one of the most common and least discussed symptoms of hormonal imbalance and perimenopause, and most women are not aware that there is an FDA approved peptide specifically for this indication. Worth knowing about.

Thymosin alpha 1: approved in 35 countries, not the US

Thymosin alpha 1 is not FDA approved, but it is approved in 35 other countries and has over 40 years of clinical trial data behind it for hepatitis B, hepatitis C, sepsis, and cancer support.

This one is a useful illustration of why FDA approval is not the only evidence lens worth considering. The clinical data on thymosin alpha 1 is extensive. The absence of FDA approval reflects the specifics of the US regulatory pathway, not an absence of evidence.

SS-31: one of the most interesting for longevity

SS-31 received FDA accelerated approval in September 2025 for Barth syndrome, a rare mitochondrial disease.

It is one of the most recently approved peptides on this list and one of the most interesting from a longevity perspective. SS-31 targets mitochondrial function specifically, protecting the inner mitochondrial membrane and improving energy production at the cellular level. The broader implications for mitochondrial health and biological aging are an active area of research, and this approval opens the door to wider investigation.

Retatrutide: where things stand right now

Retatrutide is the peptide generating the most conversation right now, and it deserves its own section.

Semaglutide is a single agonist targeting GLP-1. Tirzepatide is a dual agonist targeting GLP-1 and GIP. Retatrutide is a triple agonist, adding glucagon to both of those. Early phase 2 trial data showed body weight reductions exceeding 20%, beyond what either semaglutide or tirzepatide achieve. It is currently in phase 3 trials and not yet FDA approved.

What that means practically: it is not available through prescription. It is accessible only through the research-use-only grey market, which carries real considerations around sourcing quality and safety. The data we have is compelling but not yet as extensive as the approved GLP-1s.

I have been transparent about my own retatrutide use on this channel, including the benefits and the side effects. That video is linked above if you want the full picture. The phase 3 trial data is expected to be strong enough to complete the approval process, based on everything researchers have seen so far. But it is not there yet, and that distinction matters.

FAQ

Are peptides FDA approved?
Some are, some are not, and some are approved in other countries but not the US. Insulin has been FDA approved since 1922. Semaglutide and tirzepatide are fully approved. Others like retatrutide are in active clinical trials. The category is not uniform and should not be treated as such.

What is the difference between FDA approved and research use only peptides?
FDA approved peptides have completed rigorous clinical trials for a specific medical indication and are available through standard prescription. Research use only peptides are being sold through grey market channels, technically for research purposes, though many people are using them personally. The key differences are quality control, available safety data, and legal access.

Is retatrutide FDA approved?
Not yet. Retatrutide is currently in phase 3 clinical trials. Early data has shown body weight reductions exceeding 20%, and researchers expect it to complete the approval process. It is currently accessible only through research-use-only grey market sources.

Are supplements FDA approved?
No. Vitamins, fish oil, protein powder, magnesium and other supplements do not go through the FDA approval process. FDA approval applies to drugs seeking approval for specific medical indications, not to all substances used for health purposes.

What peptides are relevant to women's hormonal health?
PT-141, which is FDA approved for low libido, is one of the most directly relevant and least known. Tesamorelin is relevant for visceral fat accumulation related to declining growth hormone, which accelerates through the 30s and 40s. Semaglutide and tirzepatide are relevant for metabolic health and insulin resistance, which underlies many hormonal issues.

Conclusion

Peptides are not a fringe category. They are not all the same. And the decision to use or not use one should be based on understanding the mechanism, the evidence, and the risk profile of the specific peptide, not on a blanket reaction in either direction.

The FDA approval list is longer and more established than most people realise, and it provides useful context for evaluating newer peptides that are still working through the process. Watch the full YouTube video for the complete breakdown, and drop a comment if there is a specific peptide you would like me to cover in more depth.